300318.SZ
博晖创新
SZSE · Healthcare · C 制造业 · CN
CNY 4.87
−2.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 812.8M | 824.6M | 851.7M | 1.0B | 795.9M |
| Cost of Revenue | 507.6M | 498.4M | 433.6M | 590.6M | 541.1M |
| Gross Profit | 305.2M | 326.2M | 418.1M | 454.9M | 254.8M |
| Operating Expenses | |||||
| R&D Expense | 62.9M | 64.9M | 52.5M | 69.2M | 64.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 134.9M | 139.4M | 188.6M | 193.5M | 153.4M |
| Selling & Marketing Expense | 109.0M | 105.8M | 97.4M | 112.7M | 116.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 351.7M | 354.9M | 383.7M | 417.2M | 394.3M |
| Cost and Expenses | 859.2M | 853.3M | 817.3M | 1.0B | 935.5M |
| Operating Income (EBIT) | (120.2M) | (111.8M) | 35.2M | 33.8M | (127.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (179.9M) | (171.3M) | 19.9M | 33.7M | (133.8M) |
| Income Tax Expense | 875.3K | 694.9K | 11.2M | 18.0M | 4.4M |
| Bottom Line | |||||
| Net Income | (95.2M) | (91.9M) | 9.2M | (24.9M) | (78.4M) |
| Earnings from Cont. Ops | (180.7M) | (172.0M) | 8.7M | 15.7M | (138.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (95.2M) | (91.9M) | 9.2M | (24.9M) | (78.4M) |
| Per Share | |||||
| Basic EPS | (CN¥0.12) | (CN¥0.11) | CN¥0.01 | (CN¥0.03) | (CN¥0.10) |
| Diluted EPS | (CN¥0.12) | (CN¥0.11) | CN¥0.01 | (CN¥0.03) | (CN¥0.10) |
| Revenue Per Share | CN¥0.99 | CN¥1.01 | CN¥1.04 | CN¥1.28 | CN¥0.97 |
| Shares | |||||
| Basic Shares Outstanding | 818.6M | 817.1M | 818.2M | 817.4M | 817.1M |
| Diluted Shares Outstanding | 818.6M | 817.1M | 818.2M | 817.4M | 817.1M |
| Profitability Metrics | |||||
| EBITDA | — | (8.1M) | 141.5M | 144.1M | (11.9M) |
| D&A | — | 103.7M | 106.3M | 110.3M | 115.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026